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Summary
Background.  —  Single-centre  experience  in  transcatheter  closure  of  atrial  septal  defect  (ASD)
using the  Figulla® ASD  Occluder  (FSO;  Occlutech  GmbH,  Jena,  Germany)  and  the  Amplatzer®
Septal  Occluder  (ASO;  Saint-Jude  Medical,  Zaventem,  Belgium)  has  been  reported.
Aim. —  To  perform  a  retrospective  comparison  of  the  two  occluders.
Methods.  —  From  September  2009  to  December  2012,  131  consecutive  patients  underwent  per-
cutaneous  ASD  occlusion:  One  hundred  with  the  ASO  device;  31  with  the  FSO  device.
Results.  —  There  were  no  signiﬁcant  differences  between  the  two  groups  regarding  patient  char-
acteristics,  stretched  diameter,  age  and  device  size.  In  the  ASO  group,  implantation  succeeded
in all  but  two  patients  because  of  deﬁcient  rim.  Another  patient  had  device  embolization  in  the
aorta retrieved  percutaneously.  During  follow-up,  86  patients  had  no  residual  shunt  and  nine
patients  had  a  residual  shunt  (small  in  seven;  moderate  in  two).  Two  other  patients  had  persis-
tent interatrial  small  shunt  caused  by  an  adjacent  ASD  close  to  the  device.  In  the  FSO  group,
implantation  succeeded  in  all  but  two  patients:  one  because  of  deﬁcient  posterior  rim;  and
one because  of  complete  atrioventricular  block  that  resolved  after  device  extraction.  During
follow-up, no  shunt  was  observed  in  all  but  one  patient.  At  late  follow-up  (up  to  36  months),
full occlusion  was  observed  in  88  (88.0%)  patients  in  the  ASO  group  and  28  (90.3%)  patients  in
the FSO  group  (with  no  signiﬁcant  difference  between  groups).
Conclusion.  —  Transcatheter  closure  of  ASD  with  the  FSO  is  feasible  and  safe.  FSO  results  com-
pare favorably  with  ASO  results.  However,  additional  long-term  studies  that  include  more
patients are  mandatory.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’expérience  d’un  centre  dans  la  fermeture  percutanée  de  communication  interau-
riculaire (CIA)  utilisant  le  dispositif  Figulla  d’Occlutech  et  le  dispositif  Amplatzer  de  Saint-Jude
Medical est  rapportée.
Objectif.  —  Une  étude  comparative  rétrospective  entre  les  2  dispositifs  est  réalisée.
Méthodes.  —  De  septembre  2009  à  décembre  2012,  131  patients  consécutifs  ont  eu  une  fer-
meture percutanée  d’une  CIA  100  patients  avec  le  dispositif  Figulla  et  31  avec  le  dispositif
Amplatzer.
Résultats.  —  Il  n’y  avait  de  différence  signiﬁcative  entre  les  2  groupes  concernant  les  caracté-
ristiques des  patients,  la  mesure  du  diamètre  étiré  de  la  CIA,  l’âge,  et  la  taille  du  dispositif.
Dans le  groupe  Figulla,  l’implantation  a  réussi  chez  tous  les  patients  sauf  2  en  raison  de  rebord
insufﬁsant.  Un  autre  patient  a  eu  une  embolisation  de  son  dispositif  dans  l’aorte  retiré  de  fac¸on
percutanée.  Durant  le  suivi,  86  patients  n’avaient  aucun  shunt  résiduel,  9  un  shunt  résiduel
(modéré  chez  7  et  minime  chez  2  patients).  Deux  autres  patients  avaient  un  shunt  interauric-
ulaire minime  persistant  en  raison  d’une  seconde  CIA  adjacente  au  dispositif.  Dans  le  groupe
Amplatzer,  l’implantation  a  réussi  chez  tous  sauf  2  :  un  en  raison  d’un  rebord  insufﬁsant  et
l’autre dû  à  la  survenue  d’un  bloc  auriculo-ventriculaire  disparaissant  à  l’extraction  du  dis-
positif. Durant  le  suivi,  tous  les  patients  sauf  un  n’avaient  plus  de  shunt  résiduel.  Lors  du  suivi
(jusqu’à 36  mois),  une  occlusion  complète  était  observée  chez  88  patients  (88,0  %)  du  groupe
Figulla et  28  patients  (90,3  %)  du  groupe  Amplatzer,  sans  différence  signiﬁcative  entre  les  deux
groupes.
Conclusions.  —  La  fermeture  percutanée  de  CIA  avec  le  dispositif  Figulla  d’Occlutech  est  efﬁ-
cace et  sûre.  Les  résultats  du  dispositif  Figulla  se  comparent  de  fac¸on  favorable  à  ceux  obtenus
avec le  dispositif  Amplatzer.  Cependant,  d’autres  résultats  à  plus  long  terme  incluant  plus  de
patients sont  nécessaires.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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gntroductionranscatheter  closure  of  atrial  septal  defect  (ASD)  has
ecome  a  routine  procedure  for  children  and  adults  with
ystemic-to-pulmonary  ﬂow  ratio  >  1.5:1;  it  usually  carries
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w low  risk  of  periprocedural  complications  and  achieves
ood  long-term  closure  results.  In  fact,  many  devices  are
vailable  for  ASD  occlusion,  combining  different  properties,
uch  as  the  ability  to  recapture  and  redeploy  the  device
ithin  the  delivery  sheath,  the  self-centering  mechanism
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Figure 1. Amplatzer® Septal Occluder: notice the hub on the left
disc. The connecting system on the right disc uses a screwing mech-
anism, and the angle between the delivery cable and the device is
90 degrees.
Figure 2. The Figulla® ASD Occluder is a double disc system with
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to  simplify  and  achieve  good  positioning,  leading  to  a  high
occlusion  rate,  and,  ﬁnally,  a  wide  availability  of  sizes  to
close  small  to  large  defects.  The  Amplatzer® Septal  Occluder
(ASO;  Saint-Jude  Medical,  Zaventem,  Belgium)  has  been
used  most  widely  for  about  15  years,  with  favorable  follow-
up  results  [1].  More  recently,  the  Figulla® ASD  Occluder  (FSO;
Occlutech  GmbH,  Jena,  Germany)  has  been  developed,  with
structural  innovations.  In  the  present  report,  we  compare
FSO  and  ASO  results  and  outcomes  from  one  tertiary  center
in  a  series  of  131  consecutive  patients  treated  during  the
same  time  period.
Methods
Patient population
From  September  2009  to  December  2012,  131  patients
underwent  ASD  closure  with  either  an  ASO  (n  =  100)  or  an
FSO  (n  =  31;  Flex  I  device,  n  =  16;  Flex  II  device  n  =  15).  A
retrospective  comparative  analysis  of  the  two  groups  was
performed.
Devices
The  FSO  device  is  a  double  disc  system,  similar  to  the  ASO,
with  different  structural  modiﬁcations  that  make  it  quite
attractive.  This  device  is  made  of  a  nitinol  wire  mesh,  to  cre-
ate  a  smooth  and  ﬂexible  outer  layer  using  a  unique  braiding
technique.  The  two  retention  discs  are  connected  to  a  cen-
tral  4  mm  waist,  and  the  size  of  the  device  is  determined  by
the  diameter  of  the  waist,  as  usual.  The  left  atrial  disc  is  usu-
ally  12—16  mm  larger  than  the  waist  and  the  right  atrial  disc
is  8—11  mm  larger  than  the  waist  [2,3].  Polyester  patches  are
sewn  within  both  discs  and  the  waist  to  facilitate  thrombo-
genicity  and  to  increase  the  occlusion  rate.  Compared  with
the  ASO  (Fig.  1),  the  FSO  has  a  reduced  amount  of  material,
with  no  hub  on  the  left  disc  to  reduce  trauma  risk  and  clot
formation  (Fig.  2).  The  connecting  system  from  the  right
disc  to  the  distal  tip  of  the  delivery  cable  has  evolved  from
a  microscrew  initially  —  as  in  the  ASO  —  to  a  hub  attached  to
the  loader  by  two  lateral  hooks.  With  this  latter  connection,
the  double  disc  can  be  angled  some  50◦ without  tension  on
the  system  (Fig.  3).  All  these  modiﬁcations  have  increased
the  ﬂexibility  of  the  device.  The  FSO  is  available  in  different
sizes,  ranging  from  4  mm  to  40  mm  [2—4].
Implantation technique
For  both  groups,  indications  for  ASD  closure  were
pulmonary-to-systemic  ﬂow  ratio  >  1.5:1  with  right  ventricu-
lar  volume  overload.  Exclusion  criteria  were  similar  for  both
devices,  including:
• small  ASD  with  (mainly)  a  non-signiﬁcant  shunt;
• no  sign  of  right  ventricular  dilatation;
• no  reactive  elevated  pulmonary  vascular  resistance;  asso-
ciated  cardiac  lesions  requiring  surgical  repair  (mainly
associated  partial  anomalous  pulmonary  venous  return);
• deﬁcient  rim  (the  minimal  rim  accepted  was  4—5  mm,
except  for  the  anterior  rim,  which  could  be  completely
absent);
t
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S reduced amount of material and no hub on the left disc compared
ith the Amplatzer® Septal Occluder.
bleeding  condition,  such  as  untreated  ulcer;  and  con-
traindication  to  aspirin  [4—6].
Informed  written  consent  to  the  procedure  was  obtained
rom  all  patients  or  their  parents  before  closure.
The  implantation  technique  was  similar  for  both  devices.
sually,  the  procedure  was  carried  out  under  general  anaes-
hesia  with  transoesophageal  echocardiography  guidance  for
evice  implantation.  Patients  received  intravenous  heparin
100  IU/kg)  at  the  beginning  of  the  procedure.  Activated
lotting  time  measurements  were  not  usually  taken  during
he  procedure.  Device  choice  was  determined  by  measure-
ent  of  the  stretched  diameter,  using  a  compliant  balloon
atheter  (EqualizerTM Occlusion  Balloon  Catheter;  Boston
cientiﬁc,  Natick,  MA,  USA)  placed  across  the  defect  and
60  F.  Godart  et  al.
Figure 3. Figulla® ASD Occluder: the delivery cable allows a tilt
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Table  1  Patient  data  at  implantation.
ASO  group
(n  =  100)
FSO  group
(n  =  31)
P
Women/men
(n/n)
59/41  17/14  0.68a
Weight  (kg)  56.2  ±  32.8  61.0  ±  26.0  0.46b
Age  (years)  32.3  ±  25.4  36.3  ±  23.0  0.44b
Stretched
diameter  (mm)
20.4  ±  7.0  19.9  ±  5.4  0.70b
Results are expressed as number or mean ± standard deviation.
ASO: Amplatzer® Septal Occluder; FSO: Figulla® ASD Occluder.
a Chi-square test.
t
e
c
c
w
[
t
s
g
i
o
c
t
b
w
o
s
v
t
w
N
R
P
P
c
F
b
s
I
T
I
p
d
n
device  was  retrieved  by  cardiac  catheterization  the  samef up to 50◦ without any tension, facilitating placement before
elease.
ontrolled  by  colour  Doppler  transoesophageal  echocardi-
graphy,  using  the  ‘‘stop-ﬂow’’  technique.  The  size  of  the
ccluder  implanted  was  usually  the  same  as  the  stretched
iameter  ±  2  mm  [3,4,6,7].  The  appropriate  Mullins  deliv-
ry  sheath  was  then  advanced  into  the  left  atrium  over  a
uidewire  previously  placed  in  the  left  upper  pulmonary
ein.  The  introduction  of  the  occluder  within  the  delivery
heath  was  achieved  by  a  loader  for  the  FSO  ﬂushed  with
aline  serum.  The  connection  to  the  delivery  sheath  was
erformed  after  de-airing  the  delivery  sheath  under  water
o  avoid  any  risk  of  air  embolism.  Device  positioning  tech-
iques  were  similar  for  both  devices  and  correct  positioning
as  conﬁrmed  by  means  of  transoesophageal  echocardiog-
aphy  and  ﬂuoroscopy.  When  placement  was  judged  to  be
ppropriate,  the  occluder  was  released  by  unscrewing  the
elivery  cable  or  by  advancing  the  two  hooks  outside  the
oader  for  the  FSO.  The  patient  left  the  hospital  1  or  2  days
fter  implantation,  and  received  aspirin  75—160  mg  daily  for
 6-month  period.
During  follow-up,  control  transthoracic  echocardiogra-
hy  was  carried  out  1  month,  3—6  months  and  12  months
fter  implantation.  Residual  shunting  was  deﬁned  on  colour
oppler  as  trivial  (<  1  mm  colour  width),  small  (1—2  mm
olour  width),  moderate  (2—4  mm  colour  width)  and  large
>  4  mm  colour  width).
tatistical analysis
nalysis  included  patient  criteria  (i.e.  age,  sex,  weight,  size
f  the  defect  established  from  the  stretched  diameter),  suc-
ess  of  implantation,  procedure  duration,  ﬂuoroscopy  time,
adiation  dose  and  rate  of  full  occlusion  on  colour  Doppler
ransthoracic  echocardiography  at  implantation  and  during
ollow-up.  For  continuous  variables,  results  are  expressed  as
eans  and  standard  deviations  (SDs)  in  case  of  normal  distri-
ution  and  as  medians  and  SDs  otherwise.  The  normality  of
istribution  was  tested  by  the  Shapiro—Walk  test.  Categori-
al  variables  are  expressed  as  frequencies  and  percentages.
or  continuous  variables,  comparisons  between  the  two
roups  (patients  with  the  FSO  device  or  the  ASO  device)
ere  performed  using  Student’s  t-test  or  the  Mann—Whitney
d
o
ob Student’s t-test.
est,  according  to  the  distribution  of  the  variable.  For  cat-
gorical  variables,  comparisons  were  performed  using  the
hi2 test  or  Fisher’s  exact  test.  Odds  ratios  (ORs)  with  95%
onﬁdence  intervals  (CIs)  were  computed.  Because  our  study
as  not  randomized,  we  used  a  propensity  score  method
8]  to  adjust  the  analysis  for  potential  differences  between
he  two  groups  (FSO—ASO).  To  compute  the  propensity
core,  we  used  multivariable  logistic  regression,  with  the
roup  considered  as  dependent  variable  and  the  following  as
ndependent  variables:  stretched  diameter,  weight,  age,  ﬂu-
roscopy  time,  radiation  dose  and  procedure  duration.  The
omparisons  between  the  two  groups  were  then  adjusted  for
he  propensity  score.
We  used  an  analysis  of  covariance  for  continuous  varia-
les.  For  continuous  variables,  adjusted  means  with  95%  CIs
ere  computed.  The  adjusted  effect  of  the  device  on  each
utcome  was  assessed  by  using  multivariable  logistic  regres-
ion,  with  the  device  and  the  propensity  score  as  dependent
ariables.  Adjusted  ORs  with  95%  CIs  were  computed.  Statis-
ical  signiﬁcance  was  deﬁned  as  P  <  0.05.  Statistical  analyses
ere  performed  using  SAS  software  (SAS  Institute,  Inc.,  Cary,
C,  USA).
esults
atient population
atient  characteristics  are  shown  in  Table  1; there  were  41
hildren  (aged  <  18  years)  in  the  ASO  group  and  nine  in  the
SO  group.  However,  there  were  no  signiﬁcant  differences
etween  the  two  groups  concerning  sex,  weight,  age  and
tretched  diameter  at  implantation.
mmediate results of device implantation
he  results  of  device  implantation  are  shown  in  Table  2.
n  the  ASO  group,  implantation  succeeded  in  all  but  two
atients  because  of  deﬁcient  rim.  Another  patient  had
evice  embolization  in  the  transverse  aortic  arch,  which  was
oticed  on  a  chest  X-ray  in  the  hours  after  implantation;  thisay  and  the  patient  underwent  successful  transcatheter  ASD
cclusion  with  a larger  ASO,  2  months  later.  There  were  no
ther  post-procedural  complications.
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Table  2  Procedure  variables  and  follow-up.
ASO  group
(n  =  100)
FSO  group
(n  =  31)
P
Fluoroscopy  time  (minutes)  6.5  (4.5)  ±  9.51  4.6  (4.2)  ±  1.70  0.55a
Radiation  dose  (Gy/cm2)  20.1  (12.0)  ±  24.0  15.3  (11.0)  ±  13.0  0.99a
Procedure  duration  (minutes)  43.9  (40.0)  ±  15.4  47.1  (45.0)  ±  15.7  0.22a
Immediate  full  occlusion  86  (86.0)  28  (90.3)  0.29b
Late  full  occlusion  88  (88.0)  28  (90.3)  0.45c
Results are expressed as mean (median) ± standard deviation or number (%). ASO: Amplatzer® Septal Occluder; CI: conﬁdence interval;
FSO: Figulla® ASD Occluder; OR: odds ratio.
a Mann—Whitney test.
b Fisher’s exact test; OR 1.5, 95% CI 0.4—5.7 (OR of full occlusion on Doppler echocardiography, with ASO group as reference).
c Fisher’s exact test; OR 1.3, 95% CI 0.3—4.8 (OR of full occlusion on Doppler echocardiography, with ASO group as reference).
Figure 4. Transthoracic echocardiography, subcostal view: notice
the low proﬁle of the Figulla® ASD Occluder on the atrial septum.
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bIn  the  FSO  group,  implantation  succeeded  in  all  but
two  patients:  one  because  of  deﬁcient  posterior  rim;
and  the  other  because  of  the  appearance  of  complete
atrioventricular  block,  which  resolved  after  percutaneous
device  extraction.  There  were  no  other  post-procedural
complications.
On  immediate  control  echocardiography  performed  at
hospital  discharge,  full  occlusion  was  observed  in  86  (86.0%)
patients  in  the  ASO  group  and  28  (90.3%)  patients  in  the
FSO  group,  with  no  signiﬁcant  difference  between  the  two
groups  (P  =  0.29;  Fisher’s  exact  test)  (Table  2).
Late results of device implantation
In  the  ASO  group,  during  a  mean  follow-up  of
6.4  ±  7.7  months  (1—36  months),  88  patients  had  no
residual  shunt  and  nine  patients  had  a  residual  shunt  (small
in  seven;  moderate  in  two).  However,  two  of  the  88  had
a  persistent  tiny  interatrial  shunt  caused  by  another  hole
close  to  the  device,  with  no  right  ventricular  overload  (the
defect  was  ﬁnally  considered  as  closed  by  the  occluder).  In
the  FSO  group,  during  a  mean  follow-up  of  4.96  ±  7.1  months
(1—31  months),  no  shunt  was  observed  in  all  but  one  patient
(persistence  of  a  small  shunt).  Thus,  at  late  follow-up,
full  occlusion  was  seen  in  88  (88.0%)  patients  in  the  ASO
group  and  in  28  (90.3%)  patients  in  the  FSO  group  (Table  2;
Figs.  4  and  5).
The  two  groups  were  then  compared  using  the  propensity
score  method.  The  results  of  this  adjustment  are  presented
in  Tables  3  and  4,  again  showing  no  signiﬁcant  differences
between  the  two  groups  in  terms  of  patient  characteristics
at  implantation  and  during  follow-up.
Discussion
Few  studies  have  been  published  on  the  use  of  the  FSO  in
transcatheter  closure  of  ASD.  Because  implantation  of  the
FSO  device  is  very  similar  to  that  of  the  ASO,  there  is  no
learning  curve  with  this  occluder  [3].  The  main  point  of
this  study  was  to  perform  a  comparative  analysis  between
the  FSO  and  the  classic  ASO,  including  the  use  of  a  propen-
sity  score  method.  In  fact,  the  two  populations  were  quite
similar  in  terms  of  weight,  age  and  defect  size,  making
t
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wigure 5. Transthoracic echocardiography, apical four-chamber
iew (Amplatzer® Septal Occluder): the hub on the left disc is visi-
le.
he  comparison  possible.  Moreover,  our  FSO  group  had  sim-
lar  characteristics  to  those  in  published  studies  [5,6]. We
emonstrated  that  results  with  the  FSO  were  similar  to  those
ith  the  ASO,  in  terms  of  ASD  occlusion.
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Table  3  Comparison  of  continuous  variables  between  groups  1  and  2  after  adjustment  for  the  propensity  score.
ASO  group
(n  =  58)
FSO  group
(n  =  29)
Pa
Stretched  diameter  (mm)  20.3  (19.0—21.6)  20.3  (18.0—22.6)  0.99
Weight  (kg)  57.5  (52.3—62.7)  57.5  (48.1—66.9)  0.99
Age  (years)  33.4  (29.3—37.5)  33.4  (26.1—40.8)  0.99
Fluoroscopy  time  (minutes)  6.6  (4.9—8.3)  4.4  (1.4—7.4)  0.21
Radiation  dose  (Gy/cm2) 20.4  (16.2—24.6) 14.1  (6.5—21.6) 0.15
Procedure  duration  (minutes) 43.9  (40.8—47.0) 47.4  (41.9—53.0) 0.28
Results are expressed as adjusted means with 95% conﬁdence intervals. ASO: Amplatzer® Septal Occluder; FSO: Figulla® ASD Occluder.
a Analysis of covariance.
Both  FSO  and  ASO  handle  very  well  and  can  be  recaptured
or  redeployed  easily  within  the  sheath,  allowing  appropriate
repositioning,  if  necessary.  However,  the  FSO  is  character-
ized  by  a  reduction  of  material  compared  with  the  ASO.  The
absence  of  the  distal  hub  on  the  left  disc  may  be  of  beneﬁt,
in  terms  of  reducing  the  risk  of  trauma,  clot  formation  and
subsequent  systemic  embolization  [3—5,9].  However,  the
lack  of  thrombus  on  the  left  disc  in  both  groups  in  our  study
could  be  related  to  the  fact  that  only  transthoracic  echocar-
diography  was  performed  during  follow-up,  as  in  many  other
centres  [3,4,9].  Such  data  may  also  result  from  our  protocol,
and  our  insistence  that  the  procedure  is  performed  under
intravenous  heparin  at  the  dose  regimen  proposed  and  that
patients  are  given  aspirin  for  at  least  a  6-month  period  after
implantation.  In  the  same  manner,  no  stroke  was  reported  in
the  two  groups  after  implantation.  Meanwhile,  a  long-term
follow-up  study  is  mandatory  to  establish  that  there  is  no
difference  in  thrombus  formation  between  the  two  devices.
Rate  of  full  occlusion  is  very  high  with  the  FSO,  as  is
usually  observed  with  the  ASO.  Immediate  residual  shunting
of  up  to  24%  has  been  reported  with  the  FSO  [3],  but  mid-
term  results,  usually  6  months  after  the  procedure,  showed
no  residual  shunt  with  the  FSO  [3,4,6,9,10].  Similar  results
have  been  reported  with  the  ASO  [7].  Although  we  noticed
more  residual  shunt  in  the  ASO  group  than  the  FSO  group
in  the  present  study,  the  amount  of  shunting  was  minimal,
with  no  right  ventricular  overload.  In  fact,  we  observed
no  signiﬁcant  differences  between  the  two  groups,  show-
ing  the  real  non-inferiority  of  the  FSO.  It  is  likely  that  these
results  are  also  inﬂuenced  by  the  imaging  modality  used  to
diagnose  residual  shunting.  Once  more,  transthoracic  echo-
cardiography  may  be  less  sensitive  than  transoesophageal
echocardiography  in  the  depiction  of  residual  shunt  [11].
Table  4  Comparison  of  outcomes  between  groups  1  and
2  (multivariable  logistic  regression  with  adjustment  for
the  propensity  score).
Odds  ratioa 95%  CI  P
Immediate  full  occlusion  1.7  0.4—6.2  0.46
Late  full  occlusion  1.4  0.4—5.3  0.64
a Adjusted odds ratio (with 95% conﬁdence interval [CI]) of full
occlusion, with the ASO group (Amplatzer® Septal Occluder) as
reference.
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towever,  most  of  these  residual  shunts  are  not  clinically
elevant  and  will  close  with  time.
Complications  following  ASD  occlusion  with  the  FSO  are
are;  the  most  frequent  (up  to  8.9%)  is  the  occurrence
f  palpitations  due  atrial  extrasystoles  or  supraventric-
lar  tachycardia,  which  are  usually  transient  and  rarely
equire  anti-arrhythmic  therapy  [3,6,11,12].  Other  draw-
acks  included  device  embolization  in  the  pulmonary  artery
3]  or  aorta  [13], groin  haematoma  [11,12]  and  ‘‘Cobra
ormation’’  [14].  In  fact,  there  is  no  complication  associ-
ted  speciﬁcally  with  the  FSO  compared  with  the  ASO  [15].
e  observed  one  case  of  complete  atrioventricular  block
fter  placement  of  the  FSO  in  a  4-year-old  boy,  probably
elated  to  tension  on  the  atrial  septum;  this  disappeared
fter  extraction  of  the  device  and  the  patient  is  awaiting
nother  percutaneous  ASD  closure.  In  fact,  such  a  compli-
ation  is  very  rare,  but  has  also  been  reported  with  the  ASO
7,15].  In  the  ASO  group,  one  embolization  was  noticed  in
he  aorta  and  the  device  was  retrieved  in  the  hours  after
mplantation  by  cardiac  catheterization.  This  is  probably  the
ajor  complication  of  transcatheter  ASD  occlusion,  but  has
lso  been  reported  with  many  devices  [7,15].  Similar  aortic
mbolization  has  also  been  observed  with  the  FSO  [13];  the
evice  was  extracted  percutaneously  using  a  bioptome  and  a
arge  sheath.  The  authors  —  as  we  recommend  —  highlighted
he  need  for  balloon  sizing  of  the  defect  before  implanta-
ion,  to  assess  the  defect  size  and  to  avoid  undersizing,  with
ubsequent  risk  of  device  migration.
The  FSO  carries  some  drawbacks.  First,  it  is  available
ainly  in  3  mm  increments  for  the  large  device  size.  This
as  not  a  real  problem  in  our  population,  but  may  be  not
dequate  for  all  patients.  On  the  other  hand,  it  may  reduce
he  number  of  devices  that  need  to  be  stocked  in  the  car-
iac  laboratory  [4]. The  second  limitation  is  the  need  for  a
arger  introducing  sheath  for  a  device  of  equivalent  size  to
he  ASO.  Once  more,  this  may  be  a limiting  factor  in  young
hildren  because  of  the  risk  of  vascular  damage  [5].  How-
ver,  the  use  of  the  FSO  has  also  been  reported  below  the
ge  of  2 years,  with  no  major  complications  [12].  Clearly,  for
lder  children  and  adults,  the  use  of  a  larger  sheath  will  not
e  a  problem.  We  do  think  that  additional  care  should  be
aken  when  implanting  the  FSO  in  children.tudy limitations
n  the  present  study,  a  comparison  was  performed  between
he  recently  developed  FSO  and  the  classic  ASO  —  used  in
[[
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our  centre  since  November  1997  —  for  transcatheter  closure
of  ASD  during  the  same  time  period.  Our  study  is  limited
by  its  non-randomization  regarding  patient  selection,  as  are
all  published  studies,  to  our  best  knowledge.  In  the  sole
comparison  by  Pac  et  al.  [3],  there  were  no  initial  statis-
tical  differences  in  terms  of  stretched  diameter,  device  size
procedure  and  ﬂuoroscopy  time  between  the  ASO  and  FSO
groups.  Although  residual  shunting  was  higher  at  implan-
tation  with  the  FSO  in  this  study  compared  with  in  ours,
there  was  no  difference  observed  between  the  two  groups
during  late  follow-up,  in  terms  of  persistent  shunting.  How-
ever,  the  defect  size  was  smaller  (around  15  mm)  than  that
observed  in  our  present  report  (20  mm),  reﬂecting  reality
more  accurately.  Despite  larger  size  defects  in  our  study,
the  two  groups  were  very  similar  in  characteristics,  and  non-
inferiority  was  observed  with  the  FSO  compared  with  the
ASO,  in  terms  of  late  results.  In  fact,  if  the  increased  ﬂex-
ibility  of  the  FSO  is  of  beneﬁt  in  clinical  practice,  this  was
not  related  to  better  results  in  terms  of  full  occlusion,  and  it
is  not  yet  possible  to  make  any  recommendations  about  the
choice  of  FSO  or  ASO  according  to  defect  anatomy.  Finally,
long-term  study  results  are  not  available,  and  we  could  not
draw  conclusions  about  the  risk  of  device  erosion  with  the
FSO,  but  this  should  be  very  low  due  to  the  increased  ﬂexi-
bility  related  to  the  new  nitinol  meshwork.
Conclusion
To  conclude,  the  present  study  has  shown  that  the  FSO  is  safe
and  effective  in  transcatheter  ASD  closure.  Despite  a  trend
towards  lower  ﬂuoroscopy  time  and  radiation  dose  with  the
FSO  compared  with  the  ASO,  the  results  were  very  similar  in
both  groups.  The  FSO  achieved  the  same  level  of  full  occlu-
sion  during  follow-up  as  is  usually  reported  with  the  ASO.
Among  all  the  new  devices  available,  therefore,  the  FSO
seems  to  be  a  real  alternative  to  the  classic  ASO  for  ASD
closure.  However,  further  studies  with  more  patients  and  a
longer  follow-up  are  necessary  to  conﬁrm  these  preliminary
results.
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